4D Molecular Therapeutics, Inc. (FDMT) Tops Q2 EPS by 5c

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q2 EPS of ($0.63), $0.05 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $10 thousand versus the consensus estimate of $1.27 million.

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.

You May Also Be Interested In

• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
• Wolfe Research sees CNH stock flat 2027 outlook on commodity prices